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Abstract
The MEP1A gene, located on human chromosome 6p (mouse chromosome 17) in a susceptibility
region for inflammatory bowel disease (IBD), encodes the α-subunit of metalloproteinase meprin A,
which is expressed in the intestinal epithelium. This study shows a genetic association of MEP1A
with IBD in a cohort of ulcerative colitis (UC) patients. There were four single-nucleotide
polymorphisms in the coding region (P = 0.0012–0.04), and one in the 3′-untranslated region (P =
2×10−7) that displayed associations with UC. Moreover, meprin-α mRNA was decreased in inflamed
mucosa of IBD patients. Meprin-α knockout mice exhibited a more severe intestinal injury and
inflammation than their wild-type counterparts following oral administration of dextran sulfate
sodium. Collectively, the data implicate MEP1A as a UC susceptibility gene and indicate that
decreased meprin-α expression is associated with intestinal inflammation in IBD patients and in a
mouse experimental model of IBD.
INTRODUCTION
The two major forms of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's
disease (CD), are caused by genetic and environmental factors that affect the interaction
between host and microflora.1 Several IBD susceptibility genes have been identified,2,3 and
linkage analyses have implicated multiple regions within the human genome, including an area
on chromosome 6p, IBD3, that contains the HLA region, and also harbors the meprin-α gene,
MEP1A.4,5
Meprins are zinc metalloproteinases that are highly expressed in the epithelial cells of the
human and mouse intestine, and are found membrane bound and/or secreted into the lumen of
the intestine.6,7 In addition to the abundant expression in the epithelium, meprins are expressed
Correspondence: JS Bond (E-mail: jbond@psu.edu) or D Lottaz (E-mail: daniel.lottaz@insel.ch).
8These authors contributed equally to this work.
9Died on 1 January 2007.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/mi
DISCLOSURE The authors declared no conflict of interest.
NIH Public Access
Author Manuscript
Mucosal Immunol. Author manuscript; available in PMC 2009 November 1.
Published in final edited form as:

















































in human intestinal lamina propria leukocytes and in mouse mesenteric lymph nodes both in
the presence and absence of intestinal inflammation.8-10
Meprins belong to the superfamily of ‘metzincins’ that include the evolutionarily related
families of matrix metalloproteases (MMPs), serralysins, ADAMs, and astacins.11 Meprins
are unique metalloproteinases in terms of their non-catalytic domains, expression patterns,
substrate specificity, and endogenous inhibitors.12-14
Meprins are oligomers that consist of two subunits, α and/or β, that are encoded on different
chromosomes (α on human chromosome 6 and mouse chromosome 17; β on human and mouse
chromosome 18).5,15-18 Both the subunits have proteolytic activity and are capable of
degrading diverse proteins, including extracellular matrix components, such as collagen IV
laminin, nidogen, and fibronectin, but the subunits have different peptide bond specificities
and peptide substrates.13,19
In this study, complementary approaches were used to investigate the role of meprin-α in IBD.
These included a case–control association study of MEP1A polymorphisms in IBD, a study of
meprin-α expression in the intestinal mucosa of IBD patients, as well as an examination of the
functional consequences of a lack of the meprin-α subunit using meprin αKO mice. Wild-type
(WT) and αKO mice challenged with dextran sulfate sodium (DSS) elicited an experimental
model of IBD that was more severe in the αKO mice. The data presented here strongly implicate
MEP1A as an IBD susceptibility gene.
RESULTS
Genetic association of MEP1A with IBD
To identify polymorphisms in the MEP1A gene, all 14 exons were sequenced in 24 patients:
6 patients with UC, 6 with CD (none of whom carried any of the three common CD-associated
NOD2/CARD15 variants), and 12 celiac disease patients. Eight single-nucleotide
polymorphisms (SNPs) and one polymorphism consisting of a 12-nucleotide (12 nt) insert were
found (Table 1a, Figure 1). All nine polymorphisms were genotyped in 379 UC and 380 CD
patients as well as in 372 healthy controls. The human genome contains multiple copies of
MEP1A-like sequences on chromosome 9.20 Owing to the presence of these pseudogenes that
share high sequence similarities with the meprin-α gene on chromosome 6, a MEP1A-specific
sequencing strategy was developed. The genotype data and detailed information are
summarized in Supplementary Table S1 online. A pairwise linkage disequilibrium analysis
indicated strong linkage disequilibrium across the MEP1A gene (Supplementary Figure S1
online). Analysis of allele frequencies showed moderate, but statistically significant,
associations with UC for four synonymous SNPs in the coding regions of the gene (P=0.0012,
0.03, 0.04, and 0.002, in exons 8, 11, 12, and 12, respectively) (Table 1b). One SNP in the 3′-
untranslated region (UTR) (rs1059276 in exon 14) was most significantly associated with UC
(P=2×10−7). The evidence for an association with CD was weaker, supported by the 3′-UTR
only with a P-value of 0.003.
Allele frequencies for rs1059276 in our control group (risk allele frequency, 0.61) differed
from those for Caucasians (the CEU population) in Hapmap (risk allele frequency, 0.64) and
average frequency in dbSNP (risk allele frequency, 0.47). However, the association with UC
was also evident considering control allele frequencies given in these databases (P=5×10−5
and < 1×10−8 for Hapmap and dbSNP, respectively). There were no clear-cut indications for
a recessive or dominant genetic effect (Table 2). Both the multiplicative (allelic) and recessive
models are consistent with the observed association in UC. A haplotype analysis provided
some evidence that there are multiple association signals at the MEP1A locus. The risk allele
of rs1059276 was present not only in a risk haplotype as expected, but also in a protective
Banerjee et al. Page 2

















































haplotype, indicating that a second risk allele in one of the other SNPs might be present
independently (Supplementary Table S2 online). The sample size of this study limits the
statistical power to confirm independent effects.
Expression of meprin-α mRNA in the intestine of IBD patients
The mRNA levels for both meprin-α and villin-1 (a marker of differentiated epithelial cells)
were measured using quantitative reverse transcription PCR (RT-PCR) in endoscopic biopsies
from IBD patients and healthy controls. Meprin-α and meprin-α are expressed abundantly in
the terminal ileum in healthy patients (Figure 2a, left panel). Meprin-α is also expressed in the
entire large intestine (Figure 2a, right panel), albeit at two- to sixfold lower levels than in the
ileum. Villin-1 displays a similar expression pattern that probably reflects a decrease in the
relative number of differentiated epithelial cells in the colon. In contrast to meprin-α, meprin-
β mRNA expression is markedly decreased in proximal parts of the colon and is undetectable
in distal parts.
To determine whether meprin subunit expression correlates with inflammation, meprin mRNA
levels were compared in affected and unaffected regions of the sigmoid colon of IBD patients
and healthy controls. Meprin-α expression was significantly lower in inflamed mucosa of IBD
patients compared with the other groups (Figure 2b, top panel). Little-to-no meprin-β mRNA
was detectable in either unaffected or inflamed mucosa (data not shown). Expression levels of
meprin-α in CD and UC relative to average values for healthy colon were between 0.03 and
0.7 (average, 0.34) and 0.04 and 0.5 (average, 0.24), respectively. A concomitant decrease of
villin-1 mRNA indicated a decreased number of differentiated epithelial cells in affected
mucosal areas, which could account for some of the decreased meprin-α expression (Figure
2b, bottom panel). If the loss of differentiated epithelial cells was the only cause for the
decreased expression of meprin-α mRNA, the meprin-α/villin-1 ratio would be expected to
remain unchanged in the inflamed samples. However, a significantly decreased ratio of meprin-
α to villin-1 mRNA was found in affected mucosa (Figure 2c). Although the meprin-α to
villin-1 mean ratio was 0.79 (range, 0.51–1.04) in healthy controls, it was lower in the affected
regions to 0.48 (range, 0.11–0.73) in CD and 0.43 (range, 0.13–0.76) in UC groups,
respectively, indicating that the expression of meprin-α was affected to a greater extent than
of villin-1. Interestingly, meprin-α mRNA levels in unaffected mucosa of CD patients were
similar to those of healthy controls (Figure 2b, top panel). However, in UC patients, we
observed a trend of lower meprin-α mRNA levels in unaffected mucosa (mean, 0.64; range,
0.1–1.2). In summary, mucosal inflammation in IBD correlates strongly with low meprin-α
mRNA levels in CD and UC.
Generation and characterization of meprin αKO mice
To determine whether meprin-α affects the course of IBD in mice, meprin-α knockout mice
were generated and an experimental model of IBD was used. Targeted disruption of the
Mep1a gene was achieved by inserting a neomycin cassette in exon 7, the segment that codes
for the zinc-catalytic center of meprin-α (Figure 3). F1 heterozygote matings gave the expected
Mendelian genotype distribution (Supplementary Table S3 online). The homozygous meprin
αKO mice did not show any overt physical, anatomical, or histological abnormalities (data not
shown). Conventional serum chemistries were determined and all the parameters tested for
meprin αKO mice lay within the normal ranges and were similar to those of the WT counterparts
(Supplementary Table S4 online). The αKO and WT mice also showed no difference in growth
rates, as determined by body weights during different the phases of growth.
Matings of meprin αKO mice produced significantly smaller litters than their WT counterparts
(P < 0.005). The litter size of meprin αKO mice was 6.2±0.43, compared with 7.8±0.33 pups
per litter for WT mice. The smaller litter size of the αKO is reminiscent of the meprin βKO
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mice that were under-represented in a heterozygous mating.21 Both meprin-α and -β subunits
are expressed in WT mice during embryogenesis; the reduced litter sizes in αKO mice indicate
the role of meprins in development.22 It is possible that the αKO mice do not have the same
reproductive fitness as WT mice, or that there is maternal rescue in the αKO mice generated
from the heterozygous parents.
Meprin-α mRNA and protein analysis from several tissues of meprin αKO mice revealed the
lack of both, as expected (Supplementary Figure S2 online). End-point PCR of kidney mRNA
failed to detect meprin-α message in the αKO mice (Supplementary Figure S2a online) and
western blot analysis of urine samples showed detectable levels of the meprin-α protein in the
urine of WT, but not αKO, mice (Supplementary Figure S2b online). Immunohistochemical
staining of intestinal tissue detected meprin-α protein in the brush-border membranes of ileal
villi of WT but not in meprin αKO mice (Supplementary Figure S2c online).
To determine whether the disruption of the Mep1a gene affected meprin-β expression, meprin-
β mRNA, protein and activity was assessed in the meprin αKO mice (Supplementary Figure
S3 online). PCR analyses indicated similar levels of meprin-β mRNA in the kidney and
intestinal tissue in αKO and WT mice (kidney levels shown in Supplementary Figure S3a
online). Immunohistochemical analysis indicated the presence of membrane-bound meprin-β
subunits in the brush-border membrane of the ileum of both genotypes (Supplementary Figure
S3b online). In addition, the activity of meprin-β in the ileum brush-border membranes of WT
and meprin αKO mice was similar (Supplementary Figure S3c online). On the basis of these
results, it was concluded that meprin-β expression was unchanged in meprin αKO mice.
Meprin αKO mice were more susceptible to DSS-induced colitis
An experimental model of IBD was produced in mice by administering DSS in drinking water.
Administration of DSS leads to a UC-like colitis.23 Oral administration of DSS results in
toxicity to the epithelial cells of the colon and increased intestinal permeability along with
macrophage activation, which results in inflammation as a secondary phenomenon.24-27 Both
WT and meprin αKO mice began losing weight on day 4 (Figure 4a). The meprin αKO mice
lost a larger percentage of body weight (relative to day 1) than WT mice during days 5–7
(P<0.001). These results indicated that meprin αKO mice developed a more severe colitis than
WT mice.
When fecal matter of DSS-treated and control mice was monitored for occult blood to assess
rectal bleeding, the control groups had an occult score less than 1 (WT values, 0.86±0.14;
meprin αKO values, 0.71±0.29) (Figure 4b). There was an increase in fecal occult blood at 7
days in mice treated with DSS, with meprin αKO mice (mean values, 2.8±0.37) bleeding more
than the WT mice (mean values, 2.0±0.22).
Disease activity index (DAI) values were calculated as described in the Methods section
considering weight loss, stool formation, and rectal bleeding. These scores reflect the degree
of inflammation and injury in mice. The DAI values were greater for the meprin αKO mice
than for WT mice from days 4 to 7 (Figure 4c). Although the DAI score for the DSS-treated
meprin αKO mice (1.86±0.3) was significantly higher than that for controls (0.1±0.1) at day 4
(P<0.001), the DAI of DSS-treated WT mice started increasing only at day 5 (control, 0.3±0.2;
DSS, 1.0±0) (P<0.01). At day 5, the DAI for the DSS-treated meprin αKO mice (2.43±0.3)
was more than double the score for the WT group (P<0.001). By day 7, the DAI for the meprin
αKO group reached a value of 4.0±0.01, accompanied by extensive weight loss, diarrhea, and
profuse bleeding, whereas the WT group value was 2.29±0.36.
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Meprin αKO mice showed greater colon damage and inflammation
To assess the damage caused by DSS-induced colitis, colon lengths were measured and tissues
examined histologically (Figure 5). Colons from the DSS-treated groups showed prominent
shortening at necropsy on day 7 compared with those from the control groups (WT, P<0.02;
meprin αKO, P<0.0001) (Figure 5a). The decrease in colon length was more marked for meprin
αKO mice than for WT mice, indicating greater damage (P<0.04).
Sections of proximal colon of all the groups were examined histologically after hematoxylin–
eosin staining (Figure 5b, panels i–iv). Both the WT (i) and meprin αKO (ii) controls showed
normal colon morphology. DSS treatment caused marked changes in colon structure in both
the genotypes with respect to their control groups. In addition, obvious differences between
the two genotypes were observed. The DSS-treated WT mice showed some crypt destruction
and infiltrating leukocytes (iii). Greater damage in the DSS-treated meprin αKO mice was
observed, as evidenced by massive crypt destruction and ulceration. Heavy leukocytic
infiltration was seen both in the lamina propria and submucosal regions (iv).
The colon sections were scored for injury using a multifactorial scoring system.28 The DSS-
treated mice had a greater injury score than the controls of both the genotypes, with αKO having
a higher score (WT, 14.5±2.3; αKO, 21.1±1.1) (P<0.01). The injury scores of the DSS-treated
groups were normalized to their corresponding control populations to assess the degree of colon
injury brought about by DSS treatment (Figure 5c). Although the WT sections showed 1.14-
fold injury (control, 12.6±1.8; DSS, 14.5±2.3), the fold increase for meprin αKO (control 11.9
±1.3; DSS, 21.1±1.1) sections was 1.77. This difference between the two groups was significant
(P<0.04).
To assess the accumulation of polymorphonuclear leukocytes and monocytes, inflammation
of colonic mucosa was evaluated by myeloperoxidase (MPO) assay (Figure 5d). The colons
of WT and meprin αKO mice in control groups had negligible MPO activity. After DSS
treatment, increased MPO activity was observed in both WT and meprin αKO mouse colons
(P<2×10−5 and P<5×10−5, respectively). The meprin αKO mice had a significantly greater
MPO activity than their WT counterparts (P<0.007). This indicated a more severe
inflammatory reaction in the meprin αKO mice.
Colon cytokines of meprin αKO mice show greater elevation
To elucidate further the differences between the WT and αKO mice, as well as understand the
inflammatory environment upon IBD induction, colon cytokines were measured on day 5 using
an array that quantifies the levels of a panel of 16 cytokines and chemokines (Supplementary
Table S5 online). The cytokines were significantly higher in the DSS-treated WT and αKO
mice compared with their corresponding controls. DSS-treated WT and αKO mice showed a
greater than fivefold elevation of interleukin (IL)-1α, IL-1β, and IL-6 levels, compared with
their untreated controls. Furthermore, IL-12 and macrophage inflammatory protein
(MIP)-1α showed more than fivefold elevation only in the αKO mice. Seven cytokines—IL-5,
IL-6, IL-10, IL-12, monocyte chemotactic protein-1 (MCP-1) (CCL2), RANTES (CCL5), and
IFN-γ—were significantly elevated in the αKO mice compared with their WT counterparts
(P<0.05). Levels of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-9, granulocyte-macrophage colony
stimulating factor, MIP-1α (CCL3), and tumor necrosis factor-α were not significantly different
between WT and αKO DSS-treated groups (Supplementary Table S5 online). IL-6 had the
highest fold increase in both the genotypes; in WT mice, it was 28-fold higher after DSS
treatment, whereas in the αKO, the fold increase was 50-fold (Figure 6a). The other pro-
inflammatory molecules, namely IL-12, MCP-1, and RANTES, showed a two- to threefold
increase in WT mice but a four- to fivefold increase in αKO mice (Figure 6b–d). Both the
genotypes had significantly elevated levels (two- to threefold) of IL-10, an anti-inflammatory
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cytokine, in the DSS-treated colons (Figure 6e). Overall, the cytokine data show that meprin
αKO mice mount a more robust immune response than WT mice in this model of experimental
colitis.
Meprin αKO mice show higher systemic inflammation in response to DSS treatment
As colitis induction elicited a greater inflammatory response in the αKO mice, the degree of
systemic inflammation was investigated by measuring the serum nitric oxide (NO2/NO3) levels
(Figure 7a). The total nitric oxide levels in control mice of both the genotypes were low (5–7
μM). The levels in WT DSS-treated mice did not show any significant elevation until day 5,
and the increase was modest (10–15 μM). By contrast, the nitric oxide levels in the DSS-treated
meprin αKO group was increased as early as day 1 (P<0.05), and by day 5, the values were
elevated over fivefold (∼40 μM), indicating systemic inflammation in this genotype.
The same panel of 16 cytokines and chemokines, measured in the colon, was measured in the
sera of these mice to define the inflammatory environment further. In contrast to the colon
cytokines, significant differences between the two genotypes were limited to four cytokines:
IL-1β, IL-6, MCP-1, and RANTES. IL-1β levels in the DSS-treated WT mice were ninefold
higher than in controls, whereas in the αKO mice, the elevation was over 200-fold (Figure 7b).
Serum IL-6 levels in the WT mice were approximately fourfold increased after DSS treatment
compared with controls, whereas in the αKO mice, levels increased over 16-fold (Figure 7c).
Modest increases in MCP-1 and RANTES levels were also observed in the αKO DSS-treated
group (Figure 7d and e).
DISCUSSION
The positive association of the five exonic SNPs at the MEP1A locus with UC reported in this
study implicates this metalloprotease gene as a genetic determinant in this disease. Of these
five SNPs, only rs1059276 was statistically significant in CD in our study, and the P-value for
the SNP was much lower in CD (3×10−3) than in UC (2×10−7). An “in silico” replication was
performed with the publicly available data from the recent CD meta-analysis, incorporating
the data of three previous genome-wide studies.29 Although the SNPs presented here were not
specifically analyzed in these studies, “imputed” P-values for the SNPs were not significant.
30 Therefore, we conclude that although there is a strong association of meprin-α SNPs with
UC, evidence for such associations with CD remains unclear.
The two earlier genome-wide studies for UC by Fisher et al.31 and Franke et al.32 did not
report SNPs at or nearby the MEP1A locus. Notably, Fisher et al.31 analyzed only a subset of
non-synonymous SNPs. The UC-associated SNPs are all synonymous, which points to
expression levels being affected rather than enzyme function. We cannot exclude the possibility
that the MEP1A locus contains causal intronic SNPs linked to the significantly associated
exonic SNPs identified in this study. The most significant genetic association between
MEP1A SNPs and UC was the 3′-UTR C2417A SNP (dbSNP ID rs1059276). Important
functions mediated by the 3′-UTR are mRNA stability and translation regulation.33 It is,
therefore, possible that the 3′-UTR polymorphism affects constitutive meprin-α expression
levels and/or the regulation of meprin-α expression in inflamed mucosa. Consistent with this
idea is the evidence provided by the expression studies in human IBD patients in this study as
well as by a microarray study reported earlier in UC patients34 showing that there are decreased
levels of meprin-α mRNA associated with mucosal inflammation in the intestine. Our studies
show that mice lacking meprin-α protein develop a heightened inflammatory response and
greater intestinal injury than WT mice when challenged with DSS. Therefore, the genetic and
expression studies in humans and mice are consistent with a lack of meprin-α protein being
associated with greater inflammation.
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Earlier studies using inbred strains of mice that have low expression of meprin-α (e.g., as in
C3H/HeJ) showed that these mice were more vulnerable to DSS-induced IBD than mice with
high levels of expression (e.g., C57BL/6J mice).35,36 These C-strain mice contain several
differences in their major histocompatibility genes on chromosome 17 (the area of the genome
that Mep1a is linked to), and thus several genes in these mice could influence vulnerability to
intestinal damage by DSS. The study presented herein is the first to report that the disruption
of the meprin-α gene alone affects the severity of IBD.
The colon and serum cytokine profiles exhibited by the WT and αKO mice show that meprins
modulate the immune environment in a manner consistent with human IBD. Notably, two pro-
inflammatory cytokines, IL-6 and IL-12, are markedly higher in the αKO colon compared with
WT, and there is evidence that these cytokines play crucial roles in human IBD.37,38 A recent
study has shown that proIL-18 is activated by meprin B in vitro and that IL-18 is significantly
elevated in the serum of DSS-treated αKO mice compared with that in the WT mice.39 Thus,
the elevated IL-18 levels in the αKO mice also correlate with one of the hallmarks of human
colitis. Two other cytokines that are characteristically elevated in human colitis, IL-1 and tumor
necrosis factor-α, however, are not significantly different in the WT and αKO; thus, there is
not a perfect match between the meprin αKO mouse and the human IBD phenotype. The
increased colon levels of MCP-1 in the αKO mice are consistent with a positive correlation for
MCP-1 increase in both the epithelium and inflammatory cells of IBD patients.40 MIP-1α, a
chemokine that boosts the Th1 response, is significantly elevated in the DSS-treated αKO colon
but not in the WT colon; MIP-1α exacerbates IBD in mice, and may lead to the early
development of IBD in the αKO.41 In addition, there is clear evidence for greater systemic
inflammation in the αKO mice compared with WT mice as indicated by serum NO, IL-1β, and
IL-6 levels. This implies a loss of the capability of the mucosa of αKO mice to keep the disease
localized and that meprin-α is a protective factor in the intestine.
The enhanced cytokine levels of the αKO mice could result by several mechanisms, including
direct interactions of meprin isoforms with specific cytokines. For example, meprin A
(consisting of homomeric α-subunits or heteromeric α/β-subunits) is capable of cleaving and
inactivating several chemokines, such as MCP-1, RANTES, and MIP-1, and therefore a lack
of meprin A isoforms may result in an increased accumulation of these pro-inflammatory
molecules.22 By contrast, meprin B (consisting of meprin-β dimers) is capable of activating
pro-inflammatory cytokines, such as IL-1β42 and IL-18.39 Thus, the balance between the
meprin isoforms that is altered in the αKO mouse may well affect the activation and degradation
of cytokines resulting in the altered inflammatory response observed in experimental IBD.
The balance between specific MMPs and their inhibitors has also been implicated in the
pathology of intestinal inflammatory conditions.43,44 For example, MMP-2 and MMP-9 are
upregulated in human and mouse models of IBD, whereas MMP-9 enhances inflammation and
tissue damage, and MMP-2 is protective and is involved in healing and tissue resolution.45
Meprins can also degrade extracellular matrix proteins, such as collagen IV, fibronectin, and
nidogen,13 and these activities might be important in the remodeling of injured tissue in
inflammatory conditions as seen in the recovering segments of the intestine. The studies
reported herein indicate a role for meprin A in tissue regeneration/healing as opposed to tissue
damage, as well as protection against inflammatory responses.
In summary, several lines of evidence, from human genetic studies and the meprin αKO mouse
model presented here, associate MEP1A with IBD. MEP1A variants are associated with UC,
pointing to this protease as a novel susceptibility factor. The decrease of meprin-α mRNA in
the intestinal mucosa is associated with inflammation in human CD and UC patients and in the
mouse DSS-induced experimental model of IBD.
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MEP1A genotyping and genetic association study in IBD
A total of 380 CD and 379 UC patients (Supplementary Table S6 online) were recruited from
the John Radcliffe Hospital, Oxford, UK. CD and UC were diagnosed according to the standard
criteria. The healthy controls were age and sex matched and included 276 subjects randomly
chosen from general practitioner clinics around Abingdon, Oxfordshire, UK, and 96 samples
from the UK National Blood Transfusion Service. All subjects were white, non-Jewish UK
Caucasians. The study had 90% power to detect association at a P-value <0.05, given an allele
frequency of no less than 10% and a relative risk of 2. Ethics approval was obtained from the
Central Oxford Region Ethics Committee (COREC 00.083) and written consent was obtained
from all participants.
dbSNP (build 129) states a total of 255 SNPs at the MEP1A locus, the large majority of which
are intronic. There are 10 SNPs in the coding region and 6 in the 3′-UTR region. Eighty-four
SNPs have been genotyped in Hapmap. Owing to the presence of highly similar pseudogene
regions (>90% in exons 11–14) on chromosome 9, there was the risk that the genotypes in
databases were not 100% correct. Therefore, MEP1A was screened for common SNPs by
sequencing 24 samples (6 UC, 6 CD, and 12 celiac disease), thus avoiding this potential source
for errors. Only exons were analyzed, which were considered most likely to be functional.
Seven of the nine identified exonic SNPs have been genotyped in Hapmap (Table 1a).
MEP1A exons were amplified from genomic DNA and genotyped with an ABI automated
sequencer and analyzed using Lasergene (DNASTAR) (see Supplementary Table S7 online
for primers). Fulfilling the Hardy–Weinberg equilibrium was an inclusion criterion for
statistical analysis with SPSS (SPSS), the Epi Info (Centers for Disease Control and Prevention,
http://www.cdc.gov/epiinfo/), and Open Epi online epidemiologic calculators (version 2,
www.openepi.com). χ2 test was used on allele frequencies data in 2×2 contingency tables. The
extended Mantel–Haenszel χ2 test for linear trend (one degree of freedom, with continuity
correction) was performed on genotype–phenotype associations of MEP1A polymorphisms.
Linkage disequilibrium between genotyped polymorphisms was determined using GOLD.30
Quantitative RT-PCR in human intestinal specimens
The human biopsies originated from the IBD biobank of the Clinic for Gastroenterology,
Inselspital Bern, Switzerland. The study was approved by the local ethics committee, the
“Kantonale Ethikkommission Bern,” and written informed consent was obtained from all the
patients. The following were included in the study: 14 samples each of healthy mucosa from
control individuals, and inflamed and not-affected mucosa samples from CD patients and UC
patients (Supplementary Table S8 online). Anti-inflammatory medication of patients included
salazopyrin and corticoids.
RNA was extracted using the RNeasy kit (Qiagen, Hilden, Germany) and reverse transcribed
using the Reverse Transcription System Kit (Promega, Madison, WI) according to the
manufacturer's protocol. RNA samples of insufficient quality, as determined using a
Bioanalyzer (Agilent Technologies, Santa Clara, CA), were excluded from the study. cDNA
(20 ng) was added to a reaction volume of 20 μl 1× TaqMan Universal PCR Master Mix
containing uracil N-glycosylase (UNG; AmpErase, Foster City, CA) and dUTP (Applied
Biosystems, Rotkreuz, Switzerland). Target genes were quantified in duplicate on an Applied
Biosystems 7500 PCR System using Taqman probes from Applied Biosystems: Mep1A,
Mep1B, Vill-1, and TBP (assay IDs Hs01574670_m1, Hs00195535_m1, Hs01031722_g1, and
Hs00427620_m1, respectively). Sample dilution series confirmed that the RT-PCR
measurements for these genes were quantitative. Technical duplication variation was <10%.
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TATA-binding protein (TBP) was used as a housekeeping gene. Differences between mean
expression levels in the patient groups were analyzed statistically using Kruskal–Wallis and
Dunn's multiple comparison tests.
Generation of meprin α−/− mice
The Mep1a gene on chromosome 17 was inactivated by homologous recombination with a
targeted vector that inserted a neomycin-resistant cassette into the catalytic center, encoded by
exon 7 of the Mep1a gene, thereby deleting 140 bp at the targeted site. Primers 5′-
CAGGTGAGTATGACTCGAGCAGAGTAGG-3′ (containing an XhoI restriction site,
corresponding to exon7/intron7 junction) and 5′-
GATGAGGCAGCTAGCATACTGGGATTC-3′ (encoding an NheI site and corresponding to
intron 8) were used to generate a 4.9-kb amplicon from the 129×1/SvJ genomic DNA (Jackson
stock no. 000691). The XhoI–NheI-digested amplicon was ligated into XhoI–NheI cut Osdupdel
(a kind gift from Professor Oliver Smithies, University of North Carolina, Chapel Hill) to
generate Osdupdel-Mep1a-4.9. A second amplicon was made using primers 5′-
GTCAGAAGAAATCTAGACAGTAGATCAGTG-3′ (containing an XbaI restriction site and
corresponding to intron 6) and 5′-CCCACCTGTGGATCCCCAATCATAGAC-3′ (encoding
a BamHI restriction site and corresponding to exon 7). This 2.5-kb fragment was XbaI–
BamHI digested and ligated into XbaI–BamHI cut Osdupdel-Mep1a-4.9. The final vector,
Osdupdel-Mep1a, had exon 7 disrupted by a 1.2-kb neomycin cassette with an in-frame stop
codon (Figure 3a).
The targeting vector, Osdupdel-Mep1a, was electroporated into R1 mouse embryonic stem
cells.46 A total of 390 clones were screened by PCR. PCR product from the WT allele
corresponded to 3.1 kb and that of the targeted allele corresponded to 4.3 kb. The positive
clones were microinjected into blastocysts of C57BL/6 and four germline chimeras were
obtained. Electroporation and selection of targeted embryonic stem cells and subsequent
blastocyst injections were performed at the University of Michigan Transgenic Animal
Facility. Chimeric animals were crossed with C57BL/6 mice at Pennsylvania State University
College of Medicine in full compliance with animal use and care regulations. Genotypes were
determined by tail biopsies using PCR as well as Southern analysis. For Southern analysis,
HindIII was used to digest 10 μg of DNA. A 740-bp probe, corresponding to intron 8, was
generated to detect WT (4.7 kb) and disrupted (3.5 kb) alleles (Figure 3b) (see Supplementary
Table S9 online for primers).
End-point PCR
Total RNA isolated from mouse kidney using TRIzol (Invitrogen, Carlsbad, CA) was subjected
to RT-PCR with the Superscript One-Step RT-PCR kit (Invitrogen). The amount of amplicon
was obtained with the Stratagene Eagle-Eye II system equipped with Eagle-Sight software.
Glyceraldehyde-3-phosphate dehydrogenase was amplified as a control. Meprin-α primers
gave a 164-bp and meprin-β primers gave a 145-bp product (see Supplementary Table S9 online
for primers).
Immunoblotting of urinary samples and immunohistochemistry
The presence of meprin-α protein was determined by western analysis of urine from WT and
meprin αKO mice as described earlier.21
For immunohistochemistry, tissues were fixed in methyl Carnoy's solution (60% methanol,
30% chloroform, and 10% acetic acid), dehydrated in ethanol, embedded in paraffin wax, and
thin sectioned (5 μM). Sections were probed using anti-meprin-α or -β antibody.21 Digital
photographs were taken with a Nikon Eclipse E600 microscope.
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Ileum brush-border membrane preparation
Ileal samples were weighed and homogenized in 10 volumes of cold homogenization buffer
(50 mM mannitol, 2 mM Tris-Cl, pH 7.0) in the presence of Complete Mini Protease Cocktail
Inhibitor (Roche, Indianapolis, IN). CaCl2 was added to a final concentration of 10 mM and the
homogenate stirred slowly at 4°C for 15 min. After centrifugation at 3,000 g for 15 min, the
sediment was discarded. The supernatant fraction was centrifuged at 27,000 g for 30 min and
the sediment was suspended in 0.5 volumes of homogenization buffer. After a final
centrifugation at 27,000 g for 30 min, the sediment was suspended in 0.5 volumes of
homogenization buffer. Meprin-β activity was assayed as described earlier.47
Induction of experimental colitis by DSS
WT and meprin αKO litter-mates on C57BL/6×129/Sv background were used for DSS
experiments. All mice were age matched (8–9 weeks of age) and sex matched (males) and
housed under conventional nonspecific pathogen-free conditions. DSS (mol. wt, 44,000; TDB
Consultancy, Uppsala, Sweden) was administered in drinking water at 3.5 % wt/vol
concentration for 4 days, followed by water alone for 3 days. The controls were given water
only. The mice were scored daily for body weight, stool formation, and rectal bleeding. The
DAI was calculated giving equal weight to all the three parameters on a scale of 0–4; with 0
indicating no disease and 4 corresponding to maximal disease activity.24 Briefly, mice that
lost ∼5% of their body weight were given a score of 1, if their stool formation was normal and
they showed no hemoccult bleeding. The scores of 2 and 3 were assigned based on the
magnitude of weight loss accompanied with loose stool and rectal bleeding. The mice receiving
the highest score of 4 had lost more than 20% of their body weight and showed gross rectal
bleeding and diarrhea. Animals were necropsied on day 7 and the entire colon was removed
using standard surgical procedures and measured before being dissected for sample
preparation. Immediately before necropsy, stool was tested for blood using hemoccult blood
slides (Beckman Coulter, Fullerton, CA). For colon MPO and serum nitrite studies, mice were
killed on day 5. Blood was collected by cardiac puncture.
Histology
A histological examination was performed on samples of proximal colon from each animal.
The sections were stained with hematoxylin–eosin and evaluated for tissue damage by an
investigator blinded to the treatment groups using the validated scoring system of Williams et
al.28
MPO assay and serum nitric oxide levels
Colon samples were weighed and assayed for MPO activity as described.48 One unit of enzyme
activity is defined as the amount of MPO that degrades 1 mmol of H2O2 per min at room
temperature.
Blood was collected in EDTA-coated microvettes (Sarstedt, Newton, NC) and centrifuged at
10,000 g for 10 min. The serum was removed and filtered using a 10,000 MW cutoff microcon
(Millipore, Bedford, MA). The ultrafiltrate was measured for total NO2/NO3 (μm) following
the manufacturer's instructions using the standard Greiss assay kit (Cayman Chemical, Ann
Arbor, MI).
Measurement of colon and serum cytokines
Colon and serum cytokines in control and DSS-treated mice were measured using mouse
Inflammation Cytokine Array (Biolegend, San Diego, CA), following the manufacturer's
instructions. Colons were homogenized in Dulbecco's modified Eagle's medium containing
10% fetal bovine serum (0.1 g ml−1). The plate was developed using Biochemi EC3 imaging
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system (UVP, Upland, CA). Intensity of the spots was analyzed using the software provided
(Quansys Biosciences).
Statistical analysis
For analysis of genotype distributions of the F2 population, a χ2 analysis was performed on
data obtained from F1 heterozygous crosses. For all other analyses, the unpaired, two-tailed
t-test was used. A P-value of < 0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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An overview of MEP1A polymorphisms. The polymorphic sites in the human MEP1A gene
are shown in the context of the multidomain structure of the meprin-α subunit. Meprin protein
domains are S, signal peptide; Pro, propeptide; Astacin, catalytic protease domain; MAM,
meprin/A5-protein/protein-tyrosine phosphate μ; TRAF, TNF-α receptor-associated factor; I,
inserted; EGF, epidermal growth factor; TM, transmembrane; and C, cytosolic tail. The AUG
start and UGA stop codons and Poly A are italicized. The SNPs and the 12-bp insert are
indicated by their nucleotide positions. Affected amino-acid residues and their position in the
protein sequence are shown below the subunit structure. UC-associated SNPs are highlighted
in bold. Reference mRNA sequence, GenBank NM_005588, which lacks the 12-bp insert.
SNP, single-nucleotide polymorphism; TNF, tumor necrosis factor; UC, ulcerative colitis.
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Expression of meprin-α, meprin-β, and villin-1 in the intestinal mucosa of IBD patients and
healthy controls. mRNA levels, as determined by quantitative RT-PCR, are shown relative to
the average colonic expression levels of meprin-α in healthy controls. (a) Endoscopic biopsies
of three control individuals collected from the terminal ileum, cecum, proximal and distal
transverse colon, sigmoid colon, and rectum. (b) Endoscopic biopsies from the sigmoid colon
from not affected and inflamed mucosal areas of CD patients, UC patients, and healthy controls
(n=14 in each group). Shown are individual values and mean. ***P<0.001, **P<0.01,
compared with controls (Kruskal–Wallis and Dunn's multiple comparison test). (c) Ratio of
meprin-α/villin-1 mRNA levels in mucosa in CD and UC patients as compared with controls.
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IBD, inflammatory bowel disease; CD, Crohn's disease; RT-PCR, reverse transcription PCR;
UC, ulcerative colitis.
Banerjee et al. Page 16


















































Strategy for Mep1a gene disruption on mouse chromosome 17. (a) Schematic diagram of a
portion of the exon–intron structure of the WT and meprin αKO alleles. Exons (6–9) are
represented as black boxes. The neomycin cassette derived from the targeting vector
(Osdupdel: gift of O. Smithies) is depicted as a gray box in exon 7 of the KO allele. The 19-
amino-acid consensus sequence for the catalytic center of astacin family metalloproteases is
also shown. (b) Southern blot analysis of tail-derived genomic DNA. The probe used for
Southern blotting detects two HindIII-generated fragments: 3.5 kb corresponding to the WT
allele and 4.7 kb from the αKO allele. Lanes: −/−, meprin αKO DNA; +/+, WT DNA; +/−,
meprin-α heterozygous DNA. WT, wild type.
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Meprin αKO mice are more severely affected than WT mice by DSS treatment. (a) Body weight
loss in WT and meprin αKO mice was monitored over a 7-day period (n=7 mice per group).
The meprin αKO DSS group lost a greater percent of body weight than the WT DSS group
over days 4–7 (*P<0.05; **P<0.01; ***P<0.001). (b) Occult blood scores for both WT and
meprin αKO DSS groups on day 7 showed significantly higher bleeding than their
corresponding control groups (n=7 mice per group; *P<0.01; **P<0.001). (c) Disease activity
index (DAI) for the 3.5% DSS colitis model. WT and meprin αKO controls maintained DAI
scores of 0–0.5 over the 7-day period. The DAI for the meprin αKO DSS group was
significantly increased starting on day 4 (*P<0.001; compared with controls), whereas the WT
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DSS DAI increased day 5 onwards (**P<0.01; *P<0.001; compared with controls). There was
a significant difference in the DAIs of the two DSS-treated groups from days 4 to 7
(***P<0.001). DSS, dextran sulfate sodium; WT, wild type.
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Greater colon injury and inflammation in meprin αKO compared with WT mice. (a) Colon
shortening at day 7 for the mice treated with DSS. The average colon length for both WT and
meprin αKO mice administered 3.5% DSS was shorter than that for their respective controls
at day 7 (*P<0.02; #P<0.0001). The meprin αKO DSS group had shorter colons than WT DSS
group (n=7 mice per group; **P<0.04). (b) Proximal colons from WT and meprin αKO mice
were scored for injury. Representative histological sections from (i) WT control, (ii) meprin
αKO control, (iii) WT DSS-treated, and (iv) meprin αKO DSS-treated colons are shown. Colon
sections from both the control groups have normal appearance (i and ii). DSS-treated colon of
WT mouse (iii) had crypt destruction (red arrow) along with leukocytic infiltration in the lamina
propria as well as in the submucosa (black arrows). Greater damage is evident in the DSS-
treated αKO section (iv) in which massive crypt destruction is seen in an area of ulceration
(red arrow). Heavy leukocyte infiltration is evident in the lamina propria and submucosal
regions (black arrows). (c) The injury scores of WT and meprin αKO DSS-treated groups were
normalized to the corresponding control populations. Colons from meprin αKO mice show
significantly greater damage than those from WT mice (n=7 mice per group; *P<0.04). (d)
MPO activities of WT and meprin αKO colons from DSS-treated and -untreated animals were
measured from days 1 to 5. The DSS-treated mice had increased MPO activity relative to their
controls (n=6; *P<0.00002; #P<0.00005) and the colon MPO activity of DSS-treated meprin
αKO mice was significantly greater than that of the DSS-treated WT mice on days 4 and 5
(**P<0.007). DSS, dextran sulfate sodium; MPO, myeloperoxidase; WT, wild type.
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Colon cytokine and chemokine levels of WT and αKO mice treated with or without DSS were
measured on day 5 (n=5 per group). Both the DSS-treated groups had significant elevations in
their cytokine levels compared with their corresponding controls (WT DSS treated vs. control,
*P<0.03; αKO DSS treated vs. control, #P<0.05). (a) IL-6 levels were greatly elevated upon
DSS treatment, in both WT and αKO mice, to significantly higher levels in the latter
(**P<0.0001). (b–d) There were significant increases in the levels of IL-12 (**P<0.01),
MCP-1 (**P<0.00007), and RANTES (**P<0.02), in the DSS-treated αKO colons compared
with those of the DSS-treated WT group. (e) IL-10, an anti-inflammatory cytokine, was also
elevated in both genotypes after DSS treatment; meprin αKO colons had significantly higher
levels of IL-10 (**P<0.03). DSS, dextran sulfate sodium; MCP-1, monocyte chemotactic
protein-1; WT, wild type.
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Meprin αKO mice have greater systemic inflammation than WT mice. (a) Serum nitric oxide
levels of all the four groups were measured throughout the course of the study from days 1 to
5. Compared with its control group, DSS-treated meprin αKO mice showed significantly higher
levels as early as day 1(#P<0.05), whereas in the WT DSS-treated mouse, values were not
elevated until day 5 (*P<0.05). The nitrite levels in meprin αKO mice were significantly higher
than the WT DSS-treated group on days 4 and 5 (n=6; **P<0.02). (b–e) The DSS-treated
groups had increased levels of serum cytokines compared with their respective water controls
(n=7–15 mice per group; WT DSS treated vs. control, *P<0.03; αKO DSS treated vs.
control, #P<0.05). IL-1β and IL-6 levels were markedly elevated in αKO compared with WT
serum after DSS treatment (**P<0.04 and P<0.001, respectively). DSS-treated αKO mice also
had significantly higher levels of MCP-1 (**P<0.05) and RANTES (**P<0.05) than the DSS-
treated WT group. DSS, dextran sulfate sodium; IL, interleukin; MCP-1, monocyte
chemotactic protein-1; WT, wild type.
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IDa Exon Position of aa Domain dbSNPb Allelesc Affected residue
732 8 241 Astacin rs6920863d G/A SNP Syn Q
1414 11 469 TRAF rs2274658d G/T SNP Non-syn V/L
1435 11 476 TRAF rs12197930d A/G SNP Non-syn R/G
1620 12 537 TRAF G/A SNP Syn A
1674 12 555 TRAF rs4714952d G/A SNP Syn T
1825 13 606 I-domain rs2297020 A/T SNP Non-syn T/S
1909 13 634 I-domain rs2297019d A/G SNP Non-syn M/V
2326 14 — 3′-UTR 12-bp inserte —
2417f 14 — 3′-UTR rs1059276d C/A SNP —
a
Polymorphism ID according to position on mRNA GenBank acc. NM_005588 17 Nov 2006 (A of the AUG initiation codon=10).
b
Build 126 (Mar 2006).
c
Minor alleles are shown in bold.
d
Genotyped in HapMap Release #21a HapMap (Jan 2007).
e
Twelve-nt insert polymorphism: TTTGGGGCAGCT, minor allele is lack of the insert.
f






































MEP1A minor allele frequencies in IBD vs. controls




732 0.433 0.362 0.349 0.0012 0.53
1414 0.402 0.353 0.338 0.03 0.59
1435 0.039 0.024 0.029 0.27 0.58
1620 0.015 0.036 0.033 0.04 0.8
1674 0.335 0.390 0.422 0.002 0.27
1825 0.258 0.264 0.25 0.75 0.58
1909 0.256 0.258 0.254 0.97 0.9
2326 0.349 0.372 0.396 0.1 0.42
2417c 0.25 0.31 0.392 2×10
−7 0.003
CD, Crohn's disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
a
Polymorphism ID according to position on mRNA GenBank acc. NM_005588 17 Nov 2006 (A of the AUG initiation codon=10).
b
Significant associations are highlighted in bold.
c
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Table 2
Genetic models for rs1059276 in UC
Modela OR (95% CI) P-valueb











Pearson's goodness-of-fit χ2 (degree of freedom)=1.
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